Winckers et al., 2013 - Google Patents
The role of tissue factor pathway inhibitor in atherosclerosis and arterial thrombosisWinckers et al., 2013
View PDF- Document ID
- 14337699328364638759
- Author
- Winckers K
- ten Cate H
- Hackeng T
- Publication year
- Publication venue
- Blood reviews
External Links
Snippet
Tissue factor pathway inhibitor (TFPI) is the main inhibitor of tissue factor (TF)-mediated coagulation. In atherosclerotic plaques TFPI co-localizes with TF, where it is believed to play an important role in attenuating TF activity. Findings in animal models such as TFPI knockout …
- 102100008880 TFPI 0 title abstract description 495
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Winckers et al. | The role of tissue factor pathway inhibitor in atherosclerosis and arterial thrombosis | |
Van De Craen et al. | The biochemistry, physiology and pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo | |
Holm Nielsen et al. | Exploring the role of extracellular matrix proteins to develop biomarkers of plaque vulnerability and outcome | |
Olie et al. | The coagulation system in atherothrombosis: Implications for new therapeutic strategies | |
Bonnefoy et al. | Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub) endothelial VWF from cleavage by ADAMTS13 | |
Björkqvist et al. | Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III | |
Sedding et al. | The G534E polymorphism of the gene encoding the factor VII–activating protease is associated with cardiovascular risk due to increased neointima formation | |
Moons et al. | Tissue factor and coronary artery disease | |
Loeffen et al. | The impact of blood coagulability on atherosclerosis and cardiovascular disease | |
Singh et al. | The connection between C‐reactive protein and atherosclerosis | |
Lillis et al. | LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies | |
Ekmekçi et al. | Vitronectin in atherosclerotic disease | |
Bonacina et al. | Vascular pentraxin 3 controls arterial thrombosis by targeting collagen and fibrinogen induced platelets aggregation | |
Wilson et al. | Serum amyloid A, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-atherogenic manner | |
US20210395341A1 (en) | Compositions and methods for anti-thrombotic and hemostatic therapies | |
Yuan et al. | Tissue factor pathway inhibitor in atherosclerosis | |
Deininger et al. | Angiogenic proteins in brains of patients who died with cerebral malaria | |
Garlapati et al. | Targeting myeloid cell coagulation signaling blocks MAP kinase/TGF-β1–driven fibrotic remodeling in ischemic heart failure | |
Franchini et al. | The role of von Willebrand factor in hemorrhagic and thrombotic disorders | |
Kozlov et al. | Von Willebrand factor in diagnostics and treatment of cardiovascular disease: Recent advances and prospects | |
Méndez-Barbero et al. | Annexins and cardiovascular diseases: Beyond membrane trafficking and repair | |
Ullah et al. | Regulation of conformational changes in C-reactive protein alters its bioactivity | |
Tersteeg et al. | Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice | |
He et al. | Exchange protein directly activated by cAMP plays a critical role in regulation of vascular fibrinolysis | |
Donahue et al. | Disposition of tissue factor pathway inhibitor during cardiopulmonary bypass |